Chapter 177: 2.4 billion hepatitis B patients.

It has been more than two months since Xingtu Gene Company launched the AIDS-specific drug 'EBT-002 Gene Medical Drug'.

During these two months, thanks to Daxia's vast medical resources and the production capacity of 'EBT-002 Gene Medical Drug', we have been able to keep up.

Over the past two months, more than 850 million people around the world have been injected with 'EBT-002 gene therapy drug' in Daxia to treat their AIDS.

Among these 850 million people, the proportion of Daxia people is actually not high.

Thanks to years of publicity, Chinese people now avoid AIDS like the plague and everyone is afraid of it.

Therefore, thanks to Daxia's effective publicity, before the launch of 'EBT-002 Gene Medical Drug', there were only about 100 million AIDS patients in Daxia.

Two months later, only one in ten AIDS patients remained in Daxia.

Although the people of Daxia look very poor, they like to save money very much and can still come up with a mere 10,000 or 20,000 yuan.

Under such circumstances, they are naturally willing to spend money to treat their AIDS, so as of now, there are less than 10 AIDS patients in Daxia.

Among the remaining 10 people, there are those who really cannot afford the money for treatment or are reluctant to spend money for treatment.

Therefore, the current users of the 'EBT-002 gene medical drug' have actually always been foreign citizens.

Among these foreign people, the number of AIDS patients in developed countries such as the United States, Poland, and island countries is actually not large. The number of their AIDS patients is only around a few hundred thousand to one million.

The countries with the highest proportion of AIDS patients are actually those that are less developed or have poor management. For example, the number of AIDS patients in South Africa is as high as 720 million!

It can be said that among the 3900 million AIDS patients in the world, their country accounts for 18% of the population, which is really eye-catching.

As for the second place, Mozambique has 210 million AIDS patients, and the third place is India, with 200 million AIDS patients.

It can be said that in these countries with a large number of AIDS patients, either their people are relatively poor or their management is chaotic.

For people in these less developed countries, it is too much of a hassle to travel all the way to China to treat AIDS.

After all, since ancient times, going abroad has not been an easy thing, and it is also something that costs a lot of money.

Many people are afraid of going to unfamiliar countries, worrying about the security issues there and worrying that they will be bullied.

Under the current situation that the Broad Institute's 'Bode-001 AIDS specific drug' is likely to be launched first, if Xingtu Technology's 'EBT-002 Gene Medical Drug' is launched a few months later, it will be too late.

After all, compared to going abroad to Daxia to treat AIDS, they would definitely prefer to treat AIDS in their own country.

Moreover, the cost of treating AIDS in one's own country is definitely cheaper than going abroad for treatment.

If the 'EBT-002 gene medical drug' really takes a few months to be launched on the market, then the food will be out of date, right?

As for whether overseas countries will really delay the launch of the 'EBT-002 gene medical drug' by a few months?
In overseas countries where capital is king, money-for-power transactions are common practices. Overseas medical authorities only need to follow the normal review process for the "EBT-002 gene medical drug", and they can also receive money at the same time, so why not?
After all, it takes at least half a year for a drug to go from application to market, and usually more than a year.

They review the 'EBT-002 Gene Medical Drug' according to the normal process, and let it go through the normal process for half a year or even a year before it can be put on the market. No one can say anything.

Under such circumstances, Lin Feng naturally has reason to believe that various overseas medical departments will allow the 'EBT-002 Gene Medical Drug' to follow normal procedures.

It is estimated that if it can be listed in three months, it would be an easy move on their part. It is very likely to be listed in a year.

But if we really have to wait three months or a year before the drug is available on the market, how many AIDS patients will be left in the world by then, given the miraculous effectiveness of genetic medical drugs?
The remaining people are probably like the 10 people in Daxia. They are either unwilling to pay for treatment or simply have no money for treatment.

By then, even if Xingtu Technology's "EBT-002 Gene Medical Drug" was approved and could be marketed overseas, it would be too late.

This is naturally quite depressing for Xingtu Technology. After all, there are 3900 million AIDS patients in the world, but Xingtu Gene Company only has a quarter of the pie.

Not only can the remaining three quarters of the cake not be eaten, but people are also blocked from entering by despicable means. This is naturally very depressing.

Therefore, if we do not want to face such a situation, we must accelerate the overseas approval of the clinical trial application and listing of the 'EBT-002 Gene Medical Drug'!
Thinking of this, Lin Feng couldn't help but put his hand on his chin and think.

Thinking about how to get foreign countries to speed up the approval of 'EBT-002 gene medical drug' instead of dragging it out like this.

First of all, public pressure does not actually have much effect, because the right to speak in overseas public opinion is not in Lin Feng's hands.

Although Lin Feng can influence the four major Internet portals that have cooperated with Xingtu Technology, including Yahoo Portal, Weiruan MSN Portal, Penguin Portal, and New Wolf Portal, to publish some news articles that exert public pressure through the second-generation Tik Tok recommendation algorithm.

You can also use websites and apps such as Tik Tok, Bilibili, Penguin Video, YouTube, Facebook, Twitter, Weibo, and Penguin Chat to exert public pressure, but the combined influence of these things is not that great.

Because the news landscape overseas is different from that in China, people overseas still prefer to read news from authoritative newspapers such as Reuters, The Times, The Globe, The London Times, and The Sun.

After all, this is a tradition accumulated over hundreds of years and it is a matter of cultural habits. They have also developed it electronically, with paper and electronic versions published simultaneously, and the popularity rate is extremely high.

Therefore, even if Xingtu Gene Company can exert pressure through public opinion, it will make the medical review offices of those countries feel a certain amount of pressure.

But there is really no way to be sure of the effectiveness, so Xingtu Gene Company lacks the means to make a final decision.

This final measure must be something that all countries cannot refuse, and must even be eager to resolve.

After thinking about it, Lin Feng found that the solution to the problem was to develop a new special medicine.

The disease treated by this miracle drug must be close to or comparable to AIDS in terms of its harmfulness, and the number of people infected must be larger.

As for what this special medicine is?
Lin Feng came up with an idea in just a moment, and that idea was a specific medicine for hepatitis B!
Although hepatitis B is not given as much attention as AIDS in the United States, and there are no advertisements for it in every toilet and medical facility.

But the number of people who died from hepatitis B is actually not much less than that from AIDS, and the number of people infected is 6 times more than that of AIDS patients!
Because in 2015, the number of hepatitis B patients in the world reached 2.4 million, and 8000 million of them became chronic hepatitis B patients.

(End of this chapter)